<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914147</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000642265</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2009-004</secondary_id>
    <nct_id>NCT00914147</nct_id>
  </id_info>
  <brief_title>Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>Pulmonary Function Tests (PFT) in a Phase I Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Measuring how well the lungs work in patients with cancer may help doctors predict&#xD;
      how patients will respond to treatment and help plan the best treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying lung function testing in patients with locally&#xD;
      advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To obtain the distribution of DLCO, FVC, and FEV_1 by pulmonary function testing (PFT)&#xD;
           in patients with heavily pretreated locally advanced or metastatic solid tumors referred&#xD;
           to the Karmanos Cancer Institute (KCI) Phase I Clinical Trials Program.&#xD;
&#xD;
        -  To estimate the mean DLCO to within 4 units (% of predicted) of the true mean with 95%&#xD;
           confidence.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To estimate the percentage of patients who meet the defined eligibility criteria&#xD;
           (including PFT levels, especially DLCO) from the entire population enrolled in the KCI&#xD;
           Phase I Clinical Trials Program.&#xD;
&#xD;
      OUTLINE: Patients undergo pulmonary function testing comprising spirometry test, lung&#xD;
      volumes, and DLCO measurement utilizing the single-breath breath-holding technique. Patients&#xD;
      then proceed to treatment on a phase I clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 23, 2012</completion_date>
  <primary_completion_date type="Actual">August 23, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLCO, FVC, and FEV1 as measured by pulmonary function testing</measure>
    <time_frame>Prior to participation in a Phase I trial</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Pulmonary Function Test (PFT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pulmonary function testing</intervention_name>
    <description>After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.</description>
    <arm_group_label>Pulmonary Function Test (PFT)</arm_group_label>
    <other_name>PFT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Disease progressed on or after standard therapy OR there is no standard therapy for&#xD;
             the malignancy&#xD;
&#xD;
               -  Standard therapy is defined as first- or second-line therapy that has been shown&#xD;
                  to provide clinical benefit&#xD;
&#xD;
          -  Life-long non-smoker&#xD;
&#xD;
          -  No lung metastasis and/or pleural effusion causing signs or symptoms that impact&#xD;
             patient performance status&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Body mass index ≤ 35&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Ventricular arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No uncontrolled chest or abdominal pain&#xD;
&#xD;
          -  No oral or facial pain exacerbated by an oral device&#xD;
&#xD;
          -  No stress incontinence&#xD;
&#xD;
          -  No COPD, interstitial lung disease, pulmonary embolism, or hemorrhage within the past&#xD;
             6 months&#xD;
&#xD;
          -  No history of pulmonary fibrosis or pulmonary hypertension&#xD;
&#xD;
          -  No oxygen requirement at baseline&#xD;
&#xD;
          -  No asthma&#xD;
&#xD;
          -  No occupational lung disease, including, but not limited to, asbestos exposure&#xD;
&#xD;
          -  No polycythemia&#xD;
&#xD;
          -  No history of connective tissue disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior radiotherapy to the lung&#xD;
&#xD;
          -  At least 6 months since prior lung surgery&#xD;
&#xD;
          -  No prior amiodarone hydrochloride&#xD;
&#xD;
          -  No prior high-dose chemotherapy with autologous or allogeneic hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulka N. Vaishampayan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Anthony F. Shields, MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

